Frontier IP Group PLC's (LON:FIPP) Neil Crabb caught up with Proactive London's Andrew Scott to update on recent developments with its portfolio companies.
Among a number of highlights they've increased its stake in artificial intelligence (AI) firm Celerum Limited to 33.8% from 10% as well as Exscientia, which has begun phase 1 clinical trials of DSP-1181, the world’s first drug created by artificial intelligence (AI).
''The industrial traction is really important to us - it's not primarily about investment, it's about showing industry engagement and that's an underlying theme of a lot of the activity and our ability to add value within that''.
